September 8, 2026 | Mumbai : The Maharashtra FDA crackdown has widened across the state’s pharmaceutical supply chain, with regulators acting against 880 drug manufacturing and sales establishments.
The Maharashtra Food and Drug Administration conducted 2,902 inspections between June and August 2026. The inspections covered manufacturers, pharmacies and other drug-related establishments.
The department also seized illegal drugs and cosmetics valued at Rs 11.41 crore during 104 search-and-seizure operations.
The latest figures show a sharp increase in regulatory activity under FDA Commissioner Tukaram Mundhe. The campaign has focused on medicine quality, licensing, storage conditions and compliance at retail outlets.
The Maharashtra FDA crackdown also comes amid a wider enforcement drive covering food businesses across the state.
Maharashtra FDA inspected 2,902 drug establishments
Of the 2,902 inspections, 607 involved manufacturing establishments. Another 2,295 inspections covered sales establishments.
That means nearly four out of every five inspections focused on drug sales outlets.
Regulators found violations at both manufacturing and retail levels. The action resulted in 140 manufacturing establishments and 740 sales establishments facing regulatory measures.
The department suspended 677 licences and cancelled another 203 licences during the period.
The numbers highlight the scale of the Maharashtra FDA crackdown on regulatory violations.
| Enforcement measure | June-August 2026 |
| Total inspections | 2,902 |
| Manufacturing inspections | 607 |
| Sales establishment inspections | 2,295 |
| Establishments facing action | 880 |
| Manufacturing units facing action | 140 |
| Sales establishments facing action | 740 |
| Licences suspended | 677 |
| Licences cancelled | 203 |
| Search and seizure operations | 104 |
| FIRs registered | 20 |
| Arrests | 21 |
| Illegal drugs and cosmetics seized | Rs 11.41 crore |
The figures come from the Maharashtra FDA’s latest enforcement update, also reported by Business Standard, India Today and other news organisations.
What the Maharashtra FDA found during inspections
The inspections uncovered several types of compliance failures.
At manufacturing facilities, officials found shortcomings in quality-control systems and production documentation. Some establishments also faced allegations involving unauthorised or substandard medicines.
Retail inspections identified a different set of concerns.
Officials found instances of medicines being sold without proper bills or prescription requirements. Some outlets also lacked appropriate supervision by registered pharmacists.
The inspections also flagged problems involving expired medicines.
Storage conditions emerged as another important concern. Temperature-sensitive medicines require controlled storage to maintain their quality.
Insulin and vaccines were among the products for which storage conditions came under scrutiny.
The FDA also identified discrepancies between records and physical drug stocks at some establishments.
Such violations matter because medicines can lose effectiveness when manufacturers or sellers fail to follow prescribed standards.
The Maharashtra FDA crackdown therefore extends beyond counterfeit medicines. It also targets weaknesses in the legal supply, storage and sale of medicines.
104 search operations lead to Rs 11.41 crore seizure
The enforcement campaign included 104 search-and-seizure operations.
Officials seized illegal drugs and cosmetics worth Rs 11.41 crore during these operations.
The department registered 20 FIRs in connection with illegal drug and cosmetics cases. Twenty-one people were also arrested during the three-month enforcement period.
The latest seizure value remains below the Rs 13.64 crore reported for the previous financial year. However, the FDA has reported a significant rise in enforcement activity compared with the earlier period.
| Indicator | Reported change |
| Complaints | +557% |
| Complaint investigations | +378% |
| Search and seizure operations | +217% |
| Value of seized goods | +234% |
| FIR registrations | +21% |
These percentages compare the latest enforcement activity with the relevant previous financial-year figures reported by the FDA.
Enforcement activity at a glance
FDA INSPECTIONS
Sales establishments ███████████████████████ 2,295
Manufacturing units ██████ 607
REGULATORY ACTION
Sales establishments ████████████████████ 740
Manufacturing units ████ 140
Source: Maharashtra FDA data for June-August 2026.
The graphic uses plain text so it can be reproduced easily in WordPress without requiring an external chart plugin.
Drug testing also rises sharply across Maharashtra
The drug enforcement campaign forms part of a much broader testing programme.
Between June and August, Maharashtra FDA collected 37,604 samples covering food, medicines and cosmetics.
The department completed testing of 32,604 samples during the period. It classified 15,268 samples as failing prescribed standards.
Of the samples collected, 34,584 were food samples. Another 3,020 covered drugs and cosmetics.
Among the samples declared non-standard, 15,160 involved food. Another 108 involved drugs and cosmetics.
This testing surge provides important context for the Maharashtra FDA crackdown.
The regulator is not relying only on inspections of shops and factories. It is also increasing laboratory testing to identify products that may not meet prescribed standards.
Maharashtra FDA faces scrutiny over enforcement methods
The stronger enforcement campaign has also attracted judicial scrutiny.
In recent weeks, the Bombay High Court questioned aspects of FDA action in cases involving pharmaceutical companies. In one recent matter involving Cipla’s Pune unit, the court’s intervention resulted in the withdrawal of a licence cancellation order.
FDA officials have maintained that enforcement must follow due process. The latest developments underline the need for regulators to balance strong action with proper legal procedure.
This is an important part of the story because regulatory enforcement carries significant consequences for businesses.
Licence suspension or cancellation can disrupt operations and affect medicine availability. At the same time, weak enforcement can expose consumers to unsafe or unauthorised products.
The challenge for the Maharashtra FDA will therefore be to maintain both speed and procedural accuracy.
Why the crackdown matters for consumers
For consumers, the campaign highlights several basic safeguards when buying medicines.
Patients should purchase medicines from licensed pharmacies and check packaging before use. They should also verify expiry dates and follow prescription requirements for scheduled medicines.
Also Read : Tamil Nadu Assembly Row: CM Vijay Slams Udhayanidhi Stalin Over Offensive Remarks Against Women
Temperature-sensitive medicines require particular care.
Pharmacies must maintain appropriate storage conditions, especially for products that depend on controlled temperatures.
Consumers should also retain purchase bills whenever possible. Bills can help establish the source of a medicine if a quality or safety problem later emerges.
The Maharashtra FDA crackdown shows that enforcement is moving across the entire medicine supply chain.
From manufacturing plants to pharmacies, regulators are checking whether businesses meet the required standards.
What happens next?
The latest figures suggest that Maharashtra’s regulatory campaign is unlikely to slow immediately.
The FDA has expanded inspections, increased laboratory testing and stepped up action against businesses that fail to meet regulatory requirements.
At the same time, recent court proceedings show why enforcement decisions must remain evidence-based and legally sound.
For Maharashtra’s pharmaceutical sector, the message is clear: licensing, documentation, pharmacist supervision, storage and prescription rules cannot be treated as routine paperwork.
They are central to medicine safety.
The Maharashtra FDA crackdown has already produced hundreds of regulatory actions and seizures worth crores of rupees. The next test will be whether sustained inspections can improve compliance across the state’s large and complex medicine supply network.